Plasma Fractionation Market to Reach $52.6 Billion by 2031
The plasma fractionation market is projected to grow from $36.44 billion in 2026 to $52.58 billion by 2031, at a compound annual growth rate of 7.6%.
The global market for plasma fractionation is forecast to reach $52.58 billion by 2031, up from $36.44 billion in 2026, expanding at a compound annual growth rate of 7.6%, according to a report by MarketsandMarkets™.
The growth is driven by increasing demand for plasma-derived therapies across immunology, neurology, and hematology. Pharmaceutical companies, plasma collection organizations, and healthcare providers are expanding the use of these therapies to address clinical needs for conditions such as immunodeficiencies, autoimmune disorders, and bleeding disorders.
Immunoglobulins represent the largest product segment within the plasma fractionation market and are expected to see the fastest growth. This is attributed to rising demand for intravenous (IVIG) and subcutaneous (SCIG) immunoglobulins for treating immunological and neurological conditions. Therapeutic applications constitute the primary use case, and this segment is also projected to expand at a high rate.
North America held the largest share of the market in 2025, supported by established plasma collection networks and advanced healthcare infrastructure. Key players in the market include Takeda Pharmaceutical Company, Grifols, Octapharma, and Kedrion.